WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
SHANGHAI and LEVERKUSEN – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Bayer jointly announced an acquisition agreement that WuXi Biologics Germany GmbH will take over the operations of one of Bayer’s final drug product manufacturing plants in Leverkusen, Germany, and purchase the associated equipment, in combination with a long-term lease contract for the building.
Based on a manufacturing agreement to be negotiated, the plant would be operated by WuXi Biologics and serve as a back-up site for the final product manufacturing of Kovaltry™, an antihemophilic factor (recombinant). The transaction is expected to be concluded in the coming months subject to the satisfaction of customary closing conditions. Financial details were not disclosed.
“We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high quality drug product manufacturing capacities and capabilities,” said Dr. Chris Chen, CEO of WuXi Biologics. “Our business in EU, US and China market has experienced robust growth in the past few years. This additional drug product plant further confirms our commitment to ‘Global Dual Sourcing within WuXi Biologics’ strategy. WuXi Biologics will continue to expand our worldwide capacity, providing global partners with a robust and premier-quality supply chain network to benefit patients worldwide.”
Countries
Companies
Latest news
Arkema and ProLogium enter cooperation for next-generation lithium-ceramic battery materials for e-mobility with the construction of a gigafactory in Dunkirk, France
Arkema has been chosen by ProLogium, a Taiwanese technology leader in advanced batteries, as a key development and supply partner ahead of the launch of its gigafactory in France.
MOL inaugurated €1.3 billion polyol complex in Tiszaújváros, Hungary
The €1.3 billion project is MOL's largest organic investment to date, for which it has also received support from the Hungarian state. Thanks to technology of thyssenkrupp Uhde and Evonik, the plan...
BASF invests in capacity expansion of Basoflux® range of paraffin inhibitors in Tarragona, Spain.
BASF Tarragona →Increased production at the BASF site in Tarragona, Spain to support growing global demand for high-quality paraffin inhibitor chemistries. Investment reinforces BASF’s commitment to innovative and...
LYB to build integrated plastic waste recycling hub in Chemiepark Knapsack, Germany
Chemiepark Knapsack →The hub is planned to combine various advanced sorting and recycling operations, helping to address the plastic waste challenge and grow the circular economy